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Abstract 
 
Background and Purpose: Silent ischemic embolic lesions are common following transcatheter 
aortic valve implantation (TAVI). The use of embolic protection devices (EPD) may reduce the 
occurrence of these embolic lesions. Thus, a quantitative overview and credibility assessment of 
the literature was necessary to draw more a robust message about EPD. Therefore, the aim of this 
meta-analysis was to study whether the use of EPD reduces silent ischemic and clinically evident 
cerebrovascular events associated with TAVI. 
Methods: We conducted a comprehensive search to identify studies that evaluated patients 
undergoing TAVI with or without EPD. Random-effects meta-analyses were performed to 
estimate the effect of EPD compared with no-EPD during TAVI using aggregate data.  
Results: Sixteen studies involving 1170 patients (865/305 with/without EPD) fulfilled the 
inclusion criteria. The EPD-delivery success rate was reported in all studies and was achieved in 
94.5% of patients. Meta-analyses evaluating EPD versus without EPD strategies could not 
confirm or exclude any differences in terms of clinically evident stroke (RR: 0.70, 95%CI: 0.38-
1.29; P=0.26) or 30-day mortality (RR: 0.58, 95%CI: 0.20-1.64; P=0.30). There were no 
significant differences in new-single, multiple or total number of lesions. The use of EPD was 
associated with a significantly smaller ischemic volume per-lesion (SMD: -0.52, 95%CI: -0.85, -
0.20; P=0.002) and smaller total volume of lesions (SMD: -0.23, 95%CI: -0.42, -0.03; P=0.02). 
Subgroup analysis by type of valve showed an overall trend towards significant reduction in new-
lesions per-patient using EPD (SMD: -0.41, 95%Cl: -0.82, 0.00; P=0.05), driven by self-
expanding devices. 
Conclusion: The use of EPD during TAVI may be associated with smaller volume of silent 
ischemic lesions and smaller total volume of silent ischemic lesions. However, EPD may not 
reduce the number of new-single, multiple or total number of lesions. There was only very low 
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quality of evidence showing no significant differences between patients undergoing TAVI with 
or without EPD with respect to clinically evident stroke and mortality. 
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INTRODUCTION 
Transcatheter aortic valve implantation (TAVI) procedures have been associated with 
silent-ischemic cerebral embolism as assessed by diffusion-weighted magnetic resonance 
imaging (DW-MRI) or high-intensity transient signals (HITS) as assessed by transcranial 
Doppler.1-6 Embolic protection devices (EPD) might reduce the risk of cerebral embolic ischemic 
lesions, either clinically-evident cerebrovascular accidents or silent ischemic lesions in patients 
undergoing TAVI. Nonetheless, the efficacy of EPD in the TAVI setting has only been 
investigated in studies with relatively small sample sizes that are underpowered for the endpoints 
studied and thus, subject to selection biases. Hence, a comprehensive systematic review with a 
rigorous methodology for quality and credibility assessment is required to better inform decision-
making. 
We therefore conducted a systematic review and meta-analysis to assess silent-ischemic 
lesions and clinically-evident cerebrovascular outcomes associated with TAVI procedures 
performed with and without EPD. 
MATERIAL AND METHODS 
Eligibility criteria 
We included studies that evaluated patients who underwent TAVI with and without EPD. 
Studies included in the meta-analysis had to be parallel-group in design with one group having 
TAVI with EPD and the other having TAVI without EPD. To increase power of the feasibility 
analysis, we also included single-arm studies that evaluated the feasibility of performing TAVI 
with EPD. We included studies that evaluated one or more of the following outcomes within the 
30-day after TAVI: EPD-delivery success, stroke or transient ischemic attack (TIA), death, new-
silent ischemic lesions as assessed by DW-MRI or HITS, neurocognitive function as assessed by 
Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), center for 
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epidemiologic studies-depression (CES-D) scale or National Institutes of Health Stroke Scale 
(NIHSS). Endpoints, when available, were reported in accordance to Valve Academic Research 
Consortium-2.7 Reporting of outcomes had to include either crude events in each group or any 
risk/odds estimate (relative-risk [RR], hazard-ratio, odds-ratio) with 95% confidence intervals 
(CI).  
Search strategy 
We conducted a search of EMBASE, MEDLINE, CINAHL, Web of Science Core 
Collection, Cochrane Library, and conference abstracts, from conception to August 15th, 2016 
using OvidSP (Ovid Technologies). An additional study published after the systematic search 
was included due to its scientific relevance. The exact search terms used were: (“transcatheter 
aortic valve implantation” OR “TAVI” OR “transcatheter aortic valve replacement” OR 
“TAVR”) AND “embolic protection device”. There was no restriction based on language of 
study and both abstracts and unpublished studies presented in conferences were included. A flow 
diagram is shown in Figure I-Supplement, following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA).8 Institutional review board approval and 
patient consent were not required because of the nature of this study as a systematic review and 
meta-analysis. 
Study selection 
Two reviewers (RB and KS) independently and in duplicate checked all titles and abstracts 
for studies that met the inclusion criteria. The full reports of potentially relevant studies were 
retrieved, and data was independently extracted. Cohen’s kappa coefficient was calculated to 
evaluate agreement between the two reviewers at the screening levels. Any discrepancies 
between reviewers were resolved by discussion after consulting with a third investigator (MAM). 
Quality assessment 
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Risk of bias in the eligible studies was assessed separately for randomized studies, using A 
Cochrane Collaboration Risk of Bias Tool (ACROBAT),9 and Non-Randomized Studies of 
Intervention using the ACROBAT-NRSI.10 The Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) system11 was used to determine the strength of evidence 
as high, moderate, low, or very-low based on risk of bias, consistency, precision, directness, and 
publication bias.  
Data analyses 
We used RevMan (Review Manager version 5.1.7, Nordic Cochrane Centre) to perform 
random-effects meta-analysis using the Mantel-Haenszel method to determine pooled RR of EPD 
compared with non-EPD, with regards to post-TAVI outcomes, for dichotomous data. 
Standardized mean difference (SMD) was used to combine EPD/non-EPD differences in 
continuous outcomes across studies and to standardize the results to a uniform scale. Due to 
insufficient pre/post-procedural data, we excluded case series from quantitative synthesis and 
assessed them qualitatively. Intention-to-treat analysis was followed whenever possible. When 
only median and interquartile-range were available, we estimated mean and standard deviation 
using formulas proposed by Wan and colleagues.12 When only 95%CI was available, normal 
distribution was assumed when sample size was ≥100 and we calculated standard deviation using 
the equation proposed by Cochrane Handbook.13 The I2 statistic was used to assess the 
heterogeneity across studies, with an I2<25% considered low, I2 25-50% moderate, and I2>75% 
high heterogeneity. Cohen kappa agreement scores between the two reviewers with respect to 
title/abstract and full-text screening were 0.78 and 0.70, respectively, indicating moderate 
agreement. Subgroup analyses were performed to determine whether the study design or type of 
bioprosthesis influenced the treatment effect. Two-sided P-values of 0.05 were considered 
statistically significant. 
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RESULTS 
Study population 
A total of 16 studies14-29 including 1170 patients (865/305 with/without EPD) fulfilled the 
inclusion criteria for the qualitative synthesis (Figure I-Supplement). The mean age was 81.7 
years and 50.2% were female in 14 studies that reported both age and gender.14-23,26-29 The 
presence of baseline atrial fibrillation was reported in 9 studies,17-19,21,22,26,27,29 with a prevalence 
of 31.6% (285/902 patients). Previous stroke was reported in 14 studies,14-23,26-29 with a 
prevalence of 10.8% (111/1028 patients). More details can be appreciated in the Supplemental 
Results, Table I and Table II).  
Risk of bias and quality of evidence 
A complete description can be appreciated in the supplemental material and Table III-
Supplement. The quality of overall evidence was low-to-very-low with the main limitation being 
serious risk of bias and imprecision. The GRADE summary of certainty in outcomes is presented 
in Table IV-Supplement. 
30-day outcomes 
Device type, access site, procedure-related outcomes and follow-up assessment for all 
included studies reporting crude rate of events are summarized in Table V-Supplement. The 
EPD-delivery success rate was reported in all studies14-29 and was achieved in 94.5% (804/851) of 
patients, ranging 64% to 100%. All-cause mortality was reported in 9 studies17-22,27-29 and 
occurred in 3.0% (27/907) of patients; 9 studies with EPD17-22,27-29 with a 2.4% (15/626) rate and 
6 studies without EPD17,18,22,27-29 with a 2.8% (8/281) rate. The incidence of stroke was reported 
in 15 studies14-23,25-29 and occurred in 4.3% (23/1139) of patients; including 3.7% (31/843) in 15 
studies with EPD14-23,25-29 and 6.1% (18/296) in 7 studies without EPD.17,18,22,23,27-29 Meta-
analysis evaluating EPD versus without EPD strategies could not confirm or exclude a difference 
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in clinically-evident stroke (RR: 0.70, 95%CI: 0.38-1.29; P=0.26) or 30-day mortality (RR: 0.58, 
95%CI: 0.20-1.64; P=0.30), Figure II-Supplement. 
Association of EPD versus No-EPD with silent ischemic lesions: DW-MRI assessment 
The incidence of new-lesions was reported in 8 studies17,18,20,22,23,26-28 and occurred in 
88.7% (305/344) of patients; 8 studies17,18,20,22,23,26-28 used EPD and reported a 86.9% (173/199) 
rate, and 6 studies without EPD17,18,22,23,28 reporting a 91% (132/145) rate. Multiple lesions were 
reported in 4 studies17,18,23,26 and occurred in 75.9% (101/133) of patients; 4 studies using 
EPD17,18,23,26 reported a rate of 78.4% (58/74 patients), and in 3 studies without EPD17,18,23 a rate 
of 72.8% (43/59 patients) was reported. The total number of new-lesions per-patient was reported 
in 6 studies,17,18,23,28-30 and ranged from 2.2 to 8.3 lesions per-patient with EPD, and 3.1 to 16.7 
lesions per-patient without EPD. The total volume of lesions per-patient was reported in 6 
studies,17,18,23,27-29 and ranged from an average of 88 to 466 mm3 per-patient with EPD, and 168 
to 800 mm3 per-patient without EPD (Table 1). 
Meta-analyses evaluating EPD versus without EPD strategies showed no significant 
differences in terms of patients with single lesions (RR: 0.70, 95%CI: 0.25-1.96; P=0.50), and 
total number of patients with new-ischemic lesions (RR: 0.98, 95%CI: 0.89-1.07; P=0.60) Figure 
III-Supplement. There was no difference in the incidence of multiple ischemic lesions with EPD 
use (RR: 1.14, 95%CI: 0.98-1.33; P=0.10), and number of lesions per-patient (SMD: -0.19, 
95%CI: -0.71, 0.34; P=0.49) although the latter with high-degree (I2=82%) of heterogeneity, 
Figure 1. Those who underwent TAVI with EPD had lesions with smaller volume (SMD: -0.52, 
95%CI: -0.85, -0.20; P=0.002) and consequently, a smaller total volume of ischemic lesions 
(SMD: -0.23, 95%CI: -0.42, -0.03; P=0.02), Figure 1. 
Study design and type of valve subgroup analyses  
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In the subgroup analyses by study design, randomized trials, as compared with non-
randomized studies, the use of EPD did not significantly reduce the incidence of stroke (RR: 
0.70, 95%CI: 0.38-1.29; P=0.26) nor 30-day mortality (RR: 0.58, 95%CI: 0.20-1.64; P=0.30), 
Figure 2-A-B. Randomized studies showed significantly fewer number of lesions per-patient 
using EPD (SMD: -0.53, 95%CI: -1.02, -0.04; P=0.03), whereas in non-randomized studies, the 
use of EPD was associated to more silent lesions per patient (SMD: 0.69, 95%CI: 0.18-1.19; 
P=0.008). Overall difference did not show statistically significant effect (SMD: -0.19, 95%CI: -
0.71, 0.34; P=0.49), however, with significant interaction (I2=91.3%, P=0.0007). Randomized 
studies showed a significantly smaller total volume of lesions per-patient with EPD (SMD: -0.22, 
95%CI: -0.43, -0.01; P=0.04), whereas in non-randomized studies, there was no difference 
between EPD versus without EPD strategies (SMD: -0.26, 95%CI: -0.76, 0.23; P=0.29). Overall 
difference showed statistically significant effect (SMD: -0.23, 95%CI: -0.42, -0.03; P=0.02), 
Figure 2-C-D.  
Subgroup analysis according to the type of valve (Figure 3) showed no statistical difference 
in terms of patients with new-lesions (RR: 0.96, 95%CI: 0.86-1.07; P=0.49). There was an 
overall trend towards significant reduction in number of lesions per-patient using EPD (SMD: -
0.41, 95%CI: -0.82, 0.00; P=0.05), driven by the self-expanding device (interaction P=0.01, 
I2=85.1%). The use of EPD reduced the volume per lesion (SMD: -0.56, 95%CI: -0.94, -0.17; 
P=0.005), and showed a trend-towards reduction in total volume of lesions per-patient (SMD: -
0.24, 95%CI: -0.49, 0.01; P=0.06). Based on the SENTINEL trial29 that provided data on 
balloon-expandable Edwards SAPIEN-XT and SAPIEN-3 valves, separately, the EPD-arm 
showed no apparent benefit in terms of number of lesions and total volume of lesions when the 
SAPIEN-3 only (excluding SAPIEN-XT) was computed into the meta-analyses (Figure IV-
supplement). 
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Impact of EPD versus No-EPD on neurocognitive function 
The assessment of neurocognitive function for all included studies is detailed in Table 2. In 
comparative studies, patients were assessed by the MoCA before and after TAVI in 3 
studies,17,22,27 and the proportion of patients with EPD showing worsening neurocognitive 
function ranged from 10.7 to 27.3%, and from 22.7 to 33.3% in patients without EPD. Three 
studies22,27,28 used the NIHSS and the proportion of patients with EPD worsening neurocognitive 
function ranged from 0% to 17.9% and 4.5 to 22.5 % in patients without EPD. The MMSE was 
used in one study17 and did not show differences between EPD versus without EPD strategies. 
DISCUSSION 
Imaging studies reported that silent ischemic embolic lesions commonly occurred in 
patients undergoing TAVI despite the fact of using EPD. Our meta-analysis suggests that the use 
of EPD may be associated with smaller volume of ischemic lesions. Yet, EPD may not 
necessarily lead to reductions in the number of new-single, multiple and total number of lesions 
and may be associated with a numerically increased risk of HITS in certain studies. No 
significant differences were found between patients undergoing TAVI either with or without EPD 
with respect to hard end-points such us clinically-evident stroke or mortality. Failure to deliver 
the EPD occurred in approximately 5% of patients. 
Silent and clinically-evident ischemic cerebrovascular insults following aortic valve 
procedures 
Previous studies have shown an incidence of new-silent cerebral ischemic embolic lesions 
following TAVI in up to 84%, whereas new persistent clinical neurological impairment was 
about 3-6%.1-5 Silent lesions affected the two cerebral hemispheres and circulation territories in 
most of the patients.1-5 Importantly, when DW-MRI was performed at follow-up, investigators 
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agreed with the fact that ischemic lesions tended to disappear shortly after the TAVI 
procedure.1,2,17,28  
Notably, looking at SAVR populations, new cerebral ischemic lesions were reported in up 
to 60% of patients;1,31-35 lesions were often multiple, mostly clinically silent and were found to be 
of a smaller volume when compared to TAVI.1 Massé and colleagues35 detected silent cerebral 
infarctions in 61% of the patients undergoing SAVR, however, the authors reported the highest 
(17%) rate of stroke so far. This study highlights the importance of performing a systemic and 
specialized neurological assessment following cardiac interventions.35 Hereof, when routine 
neurological and DW-MRI assessment was performed in a TAVI population, clinically apparent 
neurologic deficits were matched with positive DW-MRI ischemic lesions in about 15% of 
controls in the DEFLECT-III trial.22 
It is worth to be mentioned that the available data from observational studies used 1.5-T 
MRI scanners. In this regard, the three randomized EPD studies, the MISTRAL-C,27 CLEAN-
TAVI28 and SENTINEL29 used 3-T MRI-scanners, although 11 patients in the CLEAN-TAVI 
underwent MRI in a 1.5-T scanner because of pacemaker-dependency.28 Hence, one may think 
that tiny emboli might have been missed with a 1.5-T MRI scanner; on the other hand, the use of 
a 3-T MRI-scanner, which has a higher sensitivity, may have overestimate the lesions. Therefore, 
the interpretation of the current results might be difficult to correlate with the daily-basis clinical 
practice. 
Type of TAVI device and its impact on silent ischemic embolism 
The number and volume of ischemic lesions tended to be greater with the self-expanding 
device.22,27-29 Lansky et al.22 showed that the freedom from ischemic lesions, as assessed by DW-
MRI, among patients undergoing TAVI with EPD using the balloon-expandable valve was about 
30%, whereas all patients undergoing TAVI with the self-expanding CoreValve had ischemic 
 12 
lesions despite the fact of using the TriGuard HDH (Keystone Heart, Caesarea, Israel) embolic 
deflection device that indeed, covers all brain territories. Moreover, these subjects accounted for 
the largest lesion-volumes in the EPD-group.22 This finding is in line with those of the CLEAN-
TAVI28 trial showing that almost 100% of patients exhibited new-ischemic lesions in the EPD-
arm. The SENTINEL trial29 further supports that self-expanding devices were associated with 
larger lesion volume as compared to the balloon-expandable Edwards SAPIEN-XT and SAPIEN-
3 bioprostheses, and this is taking into consideration that the trial mainly used the new-generation 
self-expanding Medtronic Evolut-R device.29 Furthermore, the sub-group of patients receiving 
the new-generation balloon-expandable SAPIEN-3 device appeared to obtain a less protective 
effect from the EPD (Figure IV-supplement). 
Silent ischemic lesions and neurocognitive function after TAVI 
There is a clear discrepancy between the incidence of new-ischemic lesions following 
TAVI and the rates of clinically-apparent neurologic impairment. Previous studies showed that 
the occurrence of silent-ischemic embolism was not associated with a measurable pre/post-TAVI 
impairment in neurocognitive function.1,2,4,5 Ghanem at al.2 showed that the presence of transient 
clinical symptoms did not correlate with ischemic lesions revealed by DW-MRI. Moreover, 
Fairbairn and coleagues5 did not find association between the number of cerebral infarcts and the 
reported mental-health and quality-of-life assessments.5 Furthermore, two studies showed a 
significant improvement in MMSE scores 3 months after TAVI.6,36  
The PROTAVI-C study17 showed no differences with and without EPD in pre/post-
procedural neurological evaluation using the NIHSS scale, nor cognitive assessment with the 
MMSE. The cognitive status evaluated by the MoCA showed significant improvement at 30-day 
compared with baseline in the EPD arm, but no differences over time without EPD.17 In this 
regard, the DEFLECT-III trial22 showed that after adjusting for age, the mean MoCA score 
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improved from baseline to discharge and 30-day in the EPD group; however, in the control 
group, the mean score declined from baseline to discharge but rebounded to approximately 
baseline levels at 30 days. Therefore, no statistically significance was observed between groups 
of treatment at 30-day follow-up.22 The SENTINEL trial29 used a comprehensive neurocognitive 
assessment tailored for TAVI patients and designed to evaluate seven domains of neurocognitive 
function, and, the use of EPD did not show any change in neurocognitive function. 
In terms of long-term follow-up, Ghanem and collages37 reported that 91% of patients 
presented preserved cognitive performance throughout the first 2 years after TAVI. Notably, the 
age of the patient but neither the absence of silent cerebral embolism, nor the use of EPD affected 
cognitive trajectory in this study.37 
Finally, one should bear in mind the present concern about silent ischemic lesions and its 
potential negative (or not) impact on neurocognitive function once TAVI will be extended to 
younger and less-sick patients exhibiting a longer life-expectancy. Thus, further investigations 
are needed to improve the identification of patients at high-risk for embolization such as those 
with extensive atherosclerosis/complex aortic atheroma, porcelain aorta, carotid disease or left 
atrial appendage thrombus.5,38-40 
Limitations 
The main limitation of this research lies with the small number of studies, patients and 
events informing each outcome, and the high-rate of loss to follow-up in most of studies. Patient-
level data was not available, precluding therefore a more robust adjustment for any differences in 
baseline data, such as atrial fibrillation, previous stroke, peripheral vascular disease, or 
anatomical variables. Also, due to insufficient data, we were not able to obtain summary mean 
estimates of pre/post-procedural values for neurocognitive endpoints. Nevertheless, in studies 
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where clinical, demographics and anatomical features were reported, populations were well-
balanced in terms of baseline characteristics across the study groups. 
CONCLUSION 
Our analysis suggests that TAVI procedures with EPD might be associated with smaller 
volume of silent ischemic lesions. However, EPD might not reduce the number of new-single, 
multiple and total number of lesions. Moreover, there was only very-low quality of evidence 
showing no significant differences between patients undergoing TAVI with or without EPD with 
respect to clinically evident stroke and mortality. Further adequately-powered research studies 
are needed to ascertain differences in patient-important outcomes before EPD should be 
incorporated into routine TAVI practice. 
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Table 1. Silent embolism 
Author,  
year Type of EPD 
Time-frame 
Imaging 
assessment 
Outcomes Patients  with EPD 
Patients  
without EPD 
Nietlispach et al.  
2010 
Embrella 
Embolic Deflector 
Pre-discharge 
DW-MRI 
A 5-mm acute cortical infarct in the right temporal 
lobe in the patient that underwent balloon aortic 
valvuloplasty alone. 
0 (0) N/A 
Naber et al.  
2012 
Claret CE Pro N/A N/A N/A N/A 
Onsea et al.  
2012 
 
Embrella Embolic 
Deflector 
<7 days 
DW-MRI 
Number of DW-MRI lesions per patient (compared 
to an historical control, n=20) 
3.2 7.2** 
Rodés-Cabau et al.  
2014 
PROTAVI-C pilot 
study 
Embrella Embolic 
Deflector 
Periprocedural 
TCD 
Day ≤7 and 30 
DW-MRI 
 
HITS 
Patients with new lesions: day ≤7 
Patients with single lesions 
Patients with multiple lesions 
Lesion volume, per lesion 
Lesion volume, per patient 
Patients with any post-TAVI lesions: day 30 
632 (347-893) 
34/34 (100) 
4 (11.8) 
30 (88.2) 
30 (20-50) 
43.0 (27.5–85.0) 
0/26 (0)* 
279 (0-505) 
6/6 (100) 
1 (16.7) 
5 (83.3) 
50 (30-70)√ 
47.5 (32.5–91.1) 
0/5 (0.0) 
Samim et al.  
2015 
Embrella Embolic 
Deflector 
Day 4 
DW-MRI 
New brain lesion 
Lesion number 
Lesion volume 
15/15 (100) 
9 (4-12) 
15.2 (11-22) 
35/37 (95) 
5 (2-7)√ 
25.1 (11-61) 
Van Mieghem et al.  
2015 
Montage Dual 
Filter 
N/A N/A N/A N/A 
Baumbach et al.  
2015 
DEFLECT I 
TriGuard 
Periprocedural 
TCD  
Day 4 and 30 
DW-MRI 
HITS 
Patients with new lesions 
Number of new lesions 
Single lesion volume 
Total lesion volume 
836±134 
23/28 (82) 
3.0 (1.8-8.0) 
30 (10-60) 
200 (30-400) 
- 
76%# 
2 (0.5-4.5)# 
150# 
300# 
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Schofer et al.  
2015 
Claret Montage 
and Claret 
Sentinel 
N/A N/A N/A N/A 
Lansky et al.  
2015 
DEFLECT III 
TriGuard 
Day 4 and 30 
DW-MRI 
Freedom from ischemic brain lesions (ITT): day 4 
New brain lesions: day 30 
Single lesion volume 
Maximum lesion volume 
7/33 (21.2) 
3/26 (11.5) 
30.9 
58.5 
3/26 (11.5) 
2/22 (9.1) 
34.8 
68.3 
Wendt et al.  
2015 
EMBOL-X 
Trans-aortic 
Day 7 
DW-MRI 
New brain lesion 
Lesion volume 
8/14 (57.1) 
88±60 
11/16 (68.8) 
168±217 
Van Gils et al.  
2015 
Claret Sentinel 
plus Wirion 
N/A N/A N/A N/A 
Schmidt et al.  
2015 
Claret Cerebral 
Protection System 
Day 3 N/A N/A N/A 
Samim et al.  
2016 
DEFLECT II Pilot 
Study 
TriGuard HDH 
Day 4 
DW-MRI 
Patients with new lesions 
Patients with single lesions 
Patients with multiple lesions 
Lesions per patient 
Mean lesion volume per patient 
10/11 (91) 
2/11 (18) 
8/11 (73) 
5.5 (0-12.0) 
13.8 (3.4-106.9) 
35/37 (95)** 
4/37 (11)** 
31/37 (84)** 
5.0 (2.0-7.0) 
25.1 (11.0-61.0)** 
Van Mieghem et al.  
2016 
MISTRAL-C 
Claret Sentinel 
Periprocedural 
TCD 
Day 5 and 30 
DW-MRI 
HITS 
Single lesion volume 
Total lesion volume 
902±444 
48 (10-60) 
95 (10-257) 
695±259 
75 (40-85) 
197 (95-525)√ 
Haussig et al.  
2016 
CLEAN-TAVI 
Claret Montage 
Periprocedural 
TCD 
Day 2, 7 and 30 
DW-MRI 
HITS 
New lesion (day 2) 
Total lesion number: day 2 
Total lesion volume: day 2 
Total lesion number: day 7 
Total lesion volume: day 7 
3196 (2522-4010) 
48/49 (98) 
8 (5.0-12.0) 
466 (349-711†) 
5 (2.75-8.0) 
205 (115-338†) 
3674 (2551-5217) 
44/45 (98) 
16 (9.75-24.25)√ 
800 (594-1407†)√ 
10 (3.0-18.0) 
472 (385-909†)√ 
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Kapadia et al.  
2017 
SENTINEL 
Claret Sentinel Day 2-7 
Total lesion number: day 2-7 
Total lesion volume: day 2-7 
3 (2-10) 
294 (69-786) 
5 (2-10) 
310 (106-860) 
 
Data presented as number/sample size (percentage), mean±SD or median (interquartile range or †95% confidence interval). DW-MRI: diffusion-weighted 
magnetic resonance imaging; TCD: transcranial Doppler; HITS: high-intensity transient signal. N/A: not available or applicable. ITT: intention-to-treat. *Two 
patients with stroke/TIA did not undergo repeat MRI due to pacemaker implantation. **Historical controls. #No contemporaneous comparator, the authors 
reported pooled data from several previous publications. Lesion volume expressed in mm3. √P=statistically significant. 
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Table 2. Neurocognitive function assessment 
 
Author,  
year EPD 
Assessment 
definitions Outcomes 
Patients  
with EPD 
Patients 
without EPD 
Nietlispach et al.  
2010 
Embrella Embolic 
Deflector 
No neurocognitive 
assessment 
N/A N/A N/A 
Naber et al. 
2012 
Claret CE Pro NIHSS 
Minor stroke (NIHSS score 2) 
Major stroke (NIHSS scores 4 and 9) 
1/40 (2.5) 
2/40 (5.0) 
N/A 
Onsea et al. 
2012 
Embrella Embolic 
Deflector 
No neurocognitive 
assessment 
N/A N/A N/A 
Rodés-Cabau et al.  
2014 
PROTAVI-C pilot 
study 
Embrella Embolic 
Deflector 
NIHSS 
MMSE 
MoCA 
MMSE: baseline 
MMSE: day 30 
MoCA: baseline 
MoCA: day 30 
28 (26-29) 
28 (26-29) 
24 (21-27) 
25 (23-28)√ 
27 (21-30) 
28 (23-30) 
24 (21-27) 
26 (23-27) 
Samim et al.  
2015 
Embrella Embolic 
Deflector 
No neurocognitive 
assessment 
N/A N/A N/A 
Van Mieghem et al. 
2015 
Montage Dual Filter 
No neurocognitive 
assessment 
N/A N/A N/A 
Baumbach et al.  
2015 
DEFLECT I 
TriGuard MoCA 
MoCA: screening 
MoCA: discharge 
MoCA: follow-up 
23 (15-29) 
24 (16-30) 
25 (15-30)√-∫∫∫ 
N/A 
Schofer et al. 
2015 
Claret Montage and 
Sentinel 
No neurocognitive 
assessment 
N/A N/A N/A 
Lansky et al. 
2015 
DEFLECT III 
TriGuard 
NIHSS 
MoCA 
NIHSS worsening: day 30 
MoCA worsening: day 30 
3.8% 
27.3% 
4.5% 
33.3% 
Wendt et al.  
2015 
EMBOL-X 
Trans-aortic 
No neurocognitive 
assessment 
N/A N/A N/A 
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Van Gils et al.  
2015 
Claret Sentinel plus 
Wirion 
No neurocognitive 
assessment 
N/A N/A N/A 
Schmidt et al.  
2015 
Claret Cerebral 
Protection System 
No neurocognitive 
assessment 
N/A N/A N/A 
Samim et al. 
2016 
DEFLECT II Pilot 
Study 
TriGuard HDH NIHSS NIHSS worsening 1/14 (7.1) N/A 
Van Mieghem et al.  
2016 
MISTRAL-C 
Claret Sentinel 
MoCA 
MMSE 
CES-D 
NIHSS 
MMSE worsening 
MoCA worsening 
CES-D worsening 
NIHSS worsening 
4% 
13% 
8% 
0% 
27%√ 
26% 
25% 
5% 
Haussig et al.  
2016 
CLEAN-TAVI 
Claret Montage 
New neurological 
symptom assessed 
by a NIHSS-
trained specialist 
NIHSS worsening: day 2 
NIHSS worsening: day 7 
NIHSS worsening: day 30 
17/44 (39) 
11/44 (25) 
7/39 (18) 
16/45 (36) 
11/45 (24) 
9/40 (23) 
Kapadia et al.  
2017 
SENTINEL 
Claret Sentinel 
Neurocognitive 
function (attention, 
executive function, 
processing speed, 
verbal and visual 
memory, mental 
status, depression) 
∆ overall composite score: day 2-7 
∆ overall composite score: day 30 
∆ overall composite score: day 90 
-0.33±0.65 
-0.09±0.44 
0.18±0.38 
-0.16±0.58 
-0.03±0.37 
0.18±0.35 
 
Data presented as number/sample size (percentage), or median (interquartile range) or absolute percentage. N/A: not available or applicable. MMSE: Mini-Mental 
State Examination. MoCA: Montreal Cognitive Assessment. CES-D: Center for Epidemiologic Studies-Depression scale. NIHSS: National Institutes of Health 
Stroke Scale. ITT: intention-to-treat. PP: per-protocol analysis. N/A: not available. √P=statistically significant. ∫∫∫: linear trend. 
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Figure legends 
 
Figure 1. Meta-analyses evaluating silent ischemic embolic lesions for patients undergoing 
transcatheter aortic valve implantation with and without embolic protection device (EPD) as 
assessed by diffusion-weighed magnetic resonance imaging. M-H: Mantel-Haenszel. CI: 
confidence interval. Std: standardized mean difference. *Data extracted from author’s oral 
presentation.30 
 
Figure 2. Meta-analyses evaluating (A) stroke and (B) mortality at 30-day (C) number of lesions, 
and (D) total volume of lesions, for patients undergoing transcatheter aortic valve implantation 
with and without embolic protection device (EPD), according to the study design. M-H: Mantel-
Haenszel. CI: confidence interval. Std: standardized mean difference. *Data extracted from 
author’s oral presentation.30 †: EPD arm included both safety and device groups. 
 
Figure 3. Meta-analyses evaluating silent ischemic embolic lesions for patients undergoing 
transcatheter aortic valve implantation with and without embolic protection device (EPD), 
according to the type of valve. M-H: Mantel-Haenszel. CI: confidence interval. Std: standardized 
mean difference. *Data extracted from author’s oral presentation.30  
